Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed its Q2 2026 10-Q quarterly report on Aug 14, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$41M
- −57.2% YoY · −20.0% QoQ
- EPS (diluted)
- −$0.70
- −22.8% YoY · −18.6% QoQ
Source: XBRL data from the CAPRICOR THERAPEUTICS, INC. (CAPR) Q2 2026 10-Q on SEC EDGAR. USD.
CAPRICOR THERAPEUTICS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no commercial products approved
- Net loss $40.7M vs $25.9M YoY; no margin figures disclosed
- Deramiocel R&D $13.1M, up 33% YoY; exosome research $0.5M, down 55%
- Cash, equivalents and marketable securities $237.9M at June 30, 2026
- PDUFA date August 22, 2026; planned amendment may extend FDA action date
Risk Factors
- Deramiocel approvability risk triggered by FDA committee’s 3–9 negative effectiveness vote on July 29, 2026
- Amended BLA risk increased by potential complete response letter or additional testing requirements
- NS arbitration risk following withdrawn injunction motion, with proceedings expected this fall
- Commercialization risk from no prior FDA-approved product or large-scale marketing experience
- Liquidity risk from continued net losses and need for additional capital to fund trials and development programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CAPRICOR THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.